Created in 2013, GenSight Biologics (Euronext: SIGHT, FR0013183985) is a Phase III clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics. Our management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served in leadership roles at several innovative ophthalmology companies.
Our initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases. Using our gene-therapy based approach, our product candidates are designed to be administered in a single treatment to each eye by intravitreal or subretinal injection in order to provide patients with a long-lasting functional cure.
Our pipeline currently comprises two lead product candidates for the treatment of sight-threatening retinal degenerative diseases, together with products in preclinical development targeting ophthalmic and neurodegenerative diseases.
We have sequentially raised €20 M in a Series A round in March 2013 and €32 M in a Series B round in July 2015, from European & US blue-chip investors, followed by a successful IPO on Euronext in July 2016, raising an additional €46 M. More recently, we successfully raised €22.5 M from leading investors in the US and Europe in June 2017.